Please use symbol entry at top right of page to search

Systemic Lupus Erythematosus Market to Advance Upto Whopping USD 10 Billion by 2030 | DelveInsight

Systemic Lupus Erythematosus market size increment is a direct consequence of expected entry of promising emerging therapies, increasing awareness of the disease, and recent advancements in research and development in the 7MM

LAS VEGAS, June 14, 2022 /PRNewswire/ -- DelveInsight's Systemic Lupus Erythematosus Market Insights report proffers a detailed comprehension of the Systemic Lupus Erythematosus market size by treatment, epidemiology, emerging therapies, market share of the individual therapies, current and forecasted Systemic Lupus Erythematosus market size from 2018 to 2030 segmented into the 7MM (the USA, EU5 , and Japan).

DelveInsight_Logo

Some of the salient features from the Systemic Lupus Erythematosus Market Report: 

  • DelveInsight analysts suggested that the Systemic Lupus Erythematosus market size in the 7MM was valued at USD 1,462 Million in 2020 and is expected to increase drastically owing to the launches of several potential emerging therapies during the study period (2018-2030).
  • Key pharmaceutical Systemic Lupus Erythematosus companies such as GlaxoSmithKline, AstraZeneca, Sanofi, Eli Lilly and Company/Nektar Therapeutics, UCB Pharma, Hoffmann-La Roche, Biogen, ImmuPharma, Xencor, Bristol Myers Squibb, Alpine Immune Sciences, Johnson & Johnson (Janssen), Idorsia Pharmaceuticals, Resolve Therapeutics, Amgen, AbbVie, Novartis, Corestem, Horizon Therapeutics, Boston Pharmaceuticals, InnoCare Pharma, Landos Biopharma, Equillium, Merck Healthcare KGaA, Gilead sciences, I-Mab Biopharma/MorphoSys AG, Chipscreen Biosciences, and others are reported to bring a significant shift in the Systemic Lupus Erythematosus.
  • The Systemic Lupus Erythematosus emerging therapies that are expected to launch in the forecast period include Dapirolizumab pegol, BIIB059, Obinutuzumab (Gazyva/Gazyvaro), IPP-201101 (Lupuzor),  and others.
  • As per DelveInsight analysis, the United States accounted for the largest Systemic Lupus Erythematosus market size that was valued at USD 1,181 million in 2020, in comparison to EU5 and Japan.
  • The current Systemic Lupus Erythematosus therapeutic landscape in the 7MM is driven by current treatment practices and the expected launch of emerging therapies.

For further information on the market impact by therapies, download the Systemic Lupus Erythematosus sample @ Systemic Lupus Erythematosus Therapeutic Scenario

Systemic Lupus Erythematosus Overview

Systemic Lupus Erythematosus (SLE) is a systemic autoimmune disease with multisystem involvement and is associated with significant morbidity and mortality. Genetic, immunological, endocrine, and environmental factors influence the loss of immunological tolerance against self-antigens leading to the formation of pathogenic autoantibodies that cause tissue damage through multiple mechanisms. The pathogenesis of Systemic Lupus Erythematosus is complex, and the understanding of SLE pathogenesis is constantly evolving. A break in the tolerance in genetically susceptible individuals, on exposure to environmental factors, leads to the activation of autoimmunity.

Systemic Lupus Erythematosus Epidemiology Segmentation

As per the assessment of DelveInsight, the total diagnosed prevalent Systemic Lupus Erythematosus population in the 7MM was found to be  651,965 in 2020 which is expected to increase during the study period.

As per DelveInsight's estimates, the United States accounted for 351,176 Systemic Lupus Erythematosus prevalent cases.

The Systemic Lupus Erythematosus Market report offers epidemiological analysis for the study period 2018-2030 in the 7MM segmented into

  • Total Diagnosed Prevalent Population of Systemic Lupus Erythematosus
  • Gender-specific Diagnosed Prevalent Population of Systemic Lupus Erythematosus
  • Age-specific Diagnosed Prevalent Population of Systemic Lupus Erythematosus
  • Severity-specific Diagnosed Prevalent Population of Systemic Lupus Erythematosus

Keen to learn how Systemic Lupus Erythematosus Epidemiological Trends are going to appear in 2030 for the 7 MM, Download @ Systemic Lupus Erythematosus Epidemiological Insights

Systemic Lupus Erythematosus Market Outlook

There is no complete cure for Systemic Lupus Erythematosus currently, but there are many treatments available to help particular symptoms. Systemic Lupus Erythematosus involves a wide range of clinical features that encompasses vascular, immune, and fibrotic manifestations along with the involvement of many organs. Systemic Lupus Erythematosus treatment includes NSAIDs and antimalarial agents, which are the first-line therapies for mild Systemic Lupus Erythematosus. In addition, glucocorticoids and cytotoxic or immunosuppressive agents—such as azathioprine, mycophenolate mofetil, cyclophosphamide, cyclosporine, and methotrexate —are used for Systemic Lupus Erythematosus treatment with organ involvement. The current Systemic Lupus Erythematosus market possesses two approved products, Benlysta (belimumab) and Saphnelo (anifrolumab-fnia)

The dynamics of the Systemic Lupus Erythematosus market is anticipated to change in the coming years owing to the improvement in the research and development activities for efficient treatment options to be available in the market. It includes several  Systemic Lupus Erythematosus pipeline therapies such as Lupuzor (also known as IPP-201101), being developed by ImmuPharma, is a 21-mer linear peptide fragment analog. ImmuPharma has completed the Phase III clinical trial for the treatment of SLE. Lupuzor demonstrated a superior response rate over placebo (61.5% vs 47.3%). ImmuPharma and Avion Pharmaceuticals signed exclusive license and development agreement for Lupuzor to fund a new 'optimized' international Phase III trial which is expected to start by 2022. Avion Pharmaceuticals has the exclusive rights for the commercialization of Lupuzor in the US. ImmuPharma retains all the rights to commercialize Lupuzor outside the US. Apart from this, Biogen is developing, BIIB059, is an investigational humanized monoclonal antibody that specifically recognizes and binds to blood DC antigen 2 (BDCA2), a pDC-specific receptor that inhibits the production of IFN-I and other inflammatory mediators when ligated. Biogen is conducting  Phase III clinical trials for the treatment of patients receiving Active SLE receiving background nonbiologic lupus standard of care. 

In addition, Dapirolizumab pegol is being developed by UCB Pharma in partnership with Biogen. It is an investigational humanized anti-CD40L antibody fragment that acts by preventing the interaction between CD40L on T-cells with CD40 on antigen-presenting cells through interactions with its receptor-CD40. The drug failed to meet its primary endpoint in the Phase II trial. However, the company continued the development of dapirolizumab pegol. The product is currently being developed jointly by UCB and Biogen to treat SLE in a Phase III trial. The topline results are expected in the first-half of 2024.

Discover more about therapy set to grab substantial Systemic Lupus Erythematosus share @ Systemic Lupus Erythematosus Market Landscape

 Systemic Lupus Erythematosus Pipeline Therapies and Key Companies

  • Itolizumab: Equillium/Biocon Limited
  • ICP-022: InnoCare Pharma
  • BOS161721: Boston Pharmaceuticals
  • NKTR-358: Nektar Therapeutics/Eli Lilly
  • ABBV-599: AbbVie
  • Deucravacitinib: Bristol Myers Squibb
  • BIIB059: Biogen
  • Gazyva/Gazyvaro (Obinutuzumab): Hoffman-La-Roche
  • Lupuzor: ImmuPharma
  • SAR441344: Sanofi

To know about more pipeline therapies covered in the report, visit @ Systemic Lupus Erythematosus Pipeline Analysis, Clinical Trials, and Emerging Therapies 

Systemic Lupus Erythematosus Market Dynamics

The expected launch of potential SLE therapies is the main factor responsible for an increase in the Systemic Lupus Erythematosus market size in the coming years, assisted by an increase in the diagnosed Systemic Lupus Erythematosus prevalent population. Also, owing to the positive outcomes of the several products during the developmental stage by many key players, and improvement in the research and development activities for efficient treatment options to be made available in the market will directly boost the Systemic Lupus Erythematosus market. The increased awareness of the disease is also considered an aspect driving the Systemic Lupus Erythematosus market growth.

On the other hand, factors such as a high annual cost and the hit and trial approach of researchers serve as setbacks for the Systemic Lupus Erythematosus market growth. The high failure rate of emerging drugs makes entering the SLE market challenging for the pharmaceutical key players. Also, several obstacles experienced in the Systemic Lupus Erythematosus pipeline, undiagnosed and unreported cases might also play as obstructions in the Systemic Lupus Erythematosus market in the future.

Know which therapy is expected to score the touchdown first @ Systemic Lupus Erythematosus Market Landscape and Forecast

Scope of the Systemic Lupus Erythematosus Market Report

  • Study Period: 2018-30
  • Coverage: 7MM [The United States, EU5 , and Japan]
  • Key Systemic Lupus Erythematosus Companies: GlaxoSmithKline, AstraZeneca, Sanofi, Eli Lilly and Company/Nektar Therapeutics, UCB Pharma, Hoffmann-La Roche, Biogen, ImmuPharma, Xencor, Bristol Myers Squibb, Alpine Immune Sciences, Johnson & Johnson (Janssen), Idorsia Pharmaceuticals, Resolve Therapeutics, Amgen, AbbVie, Novartis, Corestem, Horizon Therapeutics, Boston Pharmaceuticals, InnoCare Pharma, Landos Biopharma, Equillium, Merck Healthcare KGaA, Gilead sciences, I-Mab Biopharma/MorphoSys AG, Chipscreen Biosciences, and many others.
  • Key Systemic Lupus Erythematosus Pipeline Therapies: Dapirolizumab pegol, Itolizumab, ICP-022, NKTR-358, ABBV-599, Deucravacitinib, BIIB059, Gazyva/Gazyvaro, Lupuzor, and several others.
  • Systemic Lupus Erythematosus Therapeutic Assessment: Systemic Lupus Erythematosus current marketed and emerging therapies
  • Systemic Lupus Erythematosus Dynamics:  Systemic Lupus Erythematosus drivers and barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
  • Unmet Needs
  • KOL's views
  • Analyst's views
  • Systemic Lupus Erythematosus Access and Reimbursement

Request for a Webex demo of the report @ Systemic Lupus Erythematosus Therapeutics Market

Table of Contents 

1

Key Insights

2

Report Introduction

3

Systemic Lupus Erythematosus Market Overview at a Glance

4

Executive Summary of Systemic Lupus Erythematosus

5

Systemic Lupus Erythematosus Epidemiology and Market Methodology

6

Systemic Lupus Erythematosus: Disease Background and Overview

7

Diagnosis of Systemic Lupus Erythematosus

8

Systemic Lupus Erythematosus Treatment

9

Conclusion for Systemic Lupus Erythematosus

10

Systemic Lupus Erythematosus Epidemiology and Patient Population

11

Systemic Lupus Erythematosus Patient Journey

12

Key Endpoints in Systemic Lupus Erythematosus Clinical Trials

13

Systemic Lupus Erythematosus Marketed Therapies

14

Systemic Lupus Erythematosus Emerging Therapies

15

Systemic Lupus Erythematosus: 7 Major Market Analysis

16

Market Access and Reimbursement

17

KOL Views

18

Systemic Lupus Erythematosus Market Drivers

19

Systemic Lupus Erythematosus Market Barriers

20

Systemic Lupus Erythematosus SWOT Analysis

21

Systemic Lupus Erythematosus Unmet Needs

22

Appendix

23

DelveInsight Capabilities

24

Disclaimer

25

About DelveInsight

 

Get in touch with our Business executive  @ Systemic Lupus Erythematosus Regulatory and Patent Analysis 

Related Reports

Cutaneous Lupus Erythematosus Market

DelveInsight's "Cutaneous Lupus Erythematosus - Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Cutaneous Lupus Erythematosus, historical and forecasted epidemiology, market drivers, market barriers and key companies included like Centessa Pharmaceuticals, Bristol-Myers Squibb, Merck, Biogen, Sanofi, Zylo Therapeutics, Galapagos, Gilead Sciences, Viela Bio, Rigel Pharmaceuticals, and others.

Cervical Cancer Market

DelveInsight's 'Cervical Cancer –Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology, current treatment practices, emerging drugs like Cemiplimab, Durvalumab, Tisotumab vedotin, and key companies involved like Genentech/Roche, Iovance Biotherapeutics, Advaxis, Agenus, Akeso Biopharma, Altor BioScience, Amgen/Allergan, AstraZeneca, Avastin Biosimilars, and others

Intratumoral Cancer Therapies Market

DelveInsight's 'Intratumoral Cancer Therapies - Market Insights, Epidemiology and Market Forecast—2032' report delivers an in-depth understanding of the Intratumoral Cancer Therapies, market drivers, market barriers, unmet medical needs, and key companies involved like Amgen, Idera Pharmaceuticals, Philogen, Oncolys BioPharma, Highlight Therapeutics, Takara Bio, NanOlogy,  Istari Oncology, Moderna Therapeutics, Intensity Therapeutics, and several others.

Prostate Cancer Market 

DelveInsight's "Prostate Cancer Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Prostate cancer, emerging drugs, and key companies involved like Bayer Health Care, Amgen, Janssen Pharmaceutical, Sanofi, AstraZeneca/ Merck Sharp & Dohme, Bristol-Myers Squibb, Novartis, Hoffmann-La Roche, Pfizer, Clovis Oncology, Regeneron Pharmaceuticals, Suzhou Kintor Pharmaceutical, Eli Lilly and Company, and others.

CAR-T Pipeline Insights

DelveInsight's, "CAR-T – Pipeline Insights, 2022," report provides comprehensive insights about 250+ companies and 250+ pipeline drugs in the CAR-T pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products, key companies including, AbbVie Inc, Adaptimmune Therapeutics PLC, Amgen, Inc, Celgene, DiaCarta, Inc, Endocyte, Inc, F1 Oncology, Inc, Fate Therapeutics Inc, Gilead, Humanigen, Inc, Immune Therapeutics, Inc, Intrexon, Corp, Juno Therapeutics, Inc, Kite Pharma, Inc, Lion TCR Pte Ltd, MaxCyte, Inc, Mesoblast, Ltd. and others.

Acute Myeloid Leukemia Pipeline

DelveInsight's, "Acute Myeloid Leukemia (AML) - Pipeline Insight, 2021," report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Acute Myeloid Leukemia (AML) pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products, key companies including BioSight, GlycoMimetics, Novartis, Takeda, Menarini Group, ImmunoGen, Kartos Therapeutics, Plexxikon, Shijiazhuang Yiling Pharmaceutical, JW Pharmaceutical, Hanmi Pharmaceutical, GEMoaB Monoclonals, and several others.

Other Trending Reports

  • Hyperlipidemia Market 
  • Metastatic Cutaneous Squamous cell cancer Market
  • Plaque Modification Devices Market 
  • Mucopolysaccharidosis Market
  • Chronic smell and flavor loss Market 
  • Facial Lines Market
  • Metastatic Castration Resistant Prostate cancer Market 
  • Sarcopenia Market
  • Adalimumab Biosimilars Insight, 2022
  • Medical Marijuana Market

Browse Through Our Blog Posts

  • Systemic Lupus Erythematosus Market: How the Leading Companies are Countering the Rising Prevalence?
  • Aurinia's Lupkynis for Lupus

To Gain Rich Insights Explore Systemic Lupus Erythematosus Newsletter

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect With Us at LinkedIn | Facebook | Twitter

Contact Us

Shruti Thakur 
info@delveinsight.com  
+1(918)321-6187  
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

Cision View original content:https://www.prnewswire.com/news-releases/systemic-lupus-erythematosus-market-to-advance-upto-whopping-usd-10-billion-by-2030--delveinsight-301567685.html

SOURCE DelveInsight Business Research, LLP

Search News

Filter Results

Publication Date
Topic
Provider
  • All

News, commentary and research reports are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.